New Delhi-based Akums Drugs and Pharmaceuticals has announced its foray into nasal sprays, globally well-accepted dosage form that provides convenience of administration, improved patient compliance and quicker onset of action. Nasal sprays find their usage across multiple therapies including respiratory, neurology, analgesics among others. These can be used for local as well as systemic action. 

According to market reports, the global nasal spray market size was valued at $9.2 billion in 2021 and is projected to reach $16.9 billion by 2031, growing at a CAGR of 6.2% from 2022 to 2031. In India, driven by increasing patient pool, better diagnosis, penetration of healthcare services and rise in affordability, demand for differentiated and effective treatment options is fast growing. 

The demand for nasal spray products is not limited to developed countries but is also surging in developing countries, such as China, Brazil, and India.

In addition to addressing common respiratory conditions, nasal sprays hold promise for broader medical applications. Research and development efforts are exploring new possibilities, making nasal spray a fast and effective means of delivering medications.